A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
The purpose of this study is to identify the doses of the oral azacitidine formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2
Myelodysplastic Syndrome (MDS)
DRUG: ASTX030
â€¢ AUC ratio of AZA after administration of oral azacitidine formultions in combination with CED tablets compared with subcutaneous (SC) administration of AZA injection, Up to 1 month
The purpose of this study is to identify the doses of the oral azacitidine formulations and cedazuridine (CED) tablets which achieve a total AUC for AZA comparable to that for AZA injection at 75 mg/m2